cAMP and PKA/AKAP1 decrease mobility and promote mitochondrial translocation of Drp1. by Ronald A. Merrill (224222)

Compounds decrease polyQ toxicity in a <i>pqe-1</i> independent manner in aged animals. by Cindy Voisine (30589)

Forced activation of STAT1 causes a significant decrease in IFN-λ expression during IAV infection. by Haitao Wei (505384)

Capzb2 coimmunoprecipitates with βIII-tubulin in brain lysates and decreases tubulin polymerization in vitro. by David A. Davis (239142)

“…<p>(A) In order to avoid overlap of the heavy chain signal (∼50 kDa) with the βIII-tubulin signal (∼55 kDa) in the immunoprecipitation using the Capzb2 monoclonal antibody (mAb), the antibody was coupled to the protein G/A beads through cross-linking. βIII-tubulin and Capzb2 signals were each detected following immunoprecipitation from brain lysate with both βIII-tubulin rabbit antibody (rAb)-coupled beads and Capzb2 mAb-coupled beads. …”

BH3 Peptides induces a decrease in mitochondrial membrane potential but does not engage the Permeability Transition Pore. by Emelyn H. Shroff (163459)

Expression of Egln3 decreases tumor aggression, increases survival and normalizes glioma vascular architecture. by Vicki A. Sciorra (312082)

Effect of dilution and DMSO concentration on the interaction of NF-κB/DNA complex with the inhibitors. by Rodrigo Villagomez (685829)

Morpholino-Mediated Increase in Soluble Flt-1 Expression Results in Decreased Ocular and Tumor Neovascularization by Leah A. Owen (178086)

MiR-20a overexpression decreases LIMK1 protein expression in thyroid cancer cell lines. by Yin Xiong (342546)

Persistent organic pollutant exposures are associated with liver toxicity and decreased albumin in a highly exposed human cohort by Matthew Cave (9148916)

Programmed cell death does not cause the thoracoabdominal schisis seen in the FlnA+Fmn2 double null mice. by Gewei Lian (523268)

“…<p>Fluorescent photomicrographs show decreased rates of programmed cell death (fluorescein) between WT vs null FlnA, and WT vs null FlnA+Fmn2 cortex within the mouse sternum (WT vs null FlnA ** = p < 0.00012, Wt vs null FlnA+Fmn2 ** = p < 0.0004, null FlnA vs null FlnA+Fmn2 * = p < 0.05). …”

Decreased Platelet Count in Patients Receiving Continuous Veno-Venous Hemofiltration: A Single-Center Retrospective Study by Buyun Wu (563610)

“…<div><p>Background</p><p>A decreased platelet count may occur and portend a worse outcome in patients receiving continuous renal replacement therapy (CRRT). …”

Expression of Aβ42 decreases K_v4 protein and currents in the intact brain. by Yong Ping (233004)

Discovery of the Triazolo[1,5‑<i>a</i>]Pyrimidine-Based Derivative WS-898 as a Highly Efficacious and Orally Bioavailable ABCB1 Inhibitor Capable of Overcoming Multidrug Resistance... by Shuai Wang (109515)

Subjects:

Discovery of the Triazolo[1,5‑<i>a</i>]Pyrimidine-Based Derivative WS-898 as a Highly Efficacious and Orally Bioavailable ABCB1 Inhibitor Capable of Overcoming Multidrug Resistance... by Shuai Wang (109515)

Subjects:

Paxilline and NS11021 sensitive mitoBK channels give rise to a 190 pS conductance, which is absent in BK-negative mitoplasts. by Ewa Soltysinska (605651)

“…(<b>B</b>) Four different conductances were observed in mitoplasts from cardiomyocytes in a voltage step protocol with 2 seconds at +80 mV followed by 3 seconds at holding potential (−50 mV). …”

Compound CID 9998128 Is a Potential Multitarget Drug for Alzheimer’s Disease by Nguyen Quoc Thai (5348798)

“…Moreover, the compound dose-dependently decreases β-site amyloid precursor protein cleaving enzyme (BACE-1) activity with EC₅₀ value in micromolar range. …”

Compound CID 9998128 Is a Potential Multitarget Drug for Alzheimer’s Disease by Nguyen Quoc Thai (5348798)

“…Moreover, the compound dose-dependently decreases β-site amyloid precursor protein cleaving enzyme (BACE-1) activity with EC₅₀ value in micromolar range. …”

25OHD₃ increases expression of TRPV5 in the kidneys of CYP27B1^-/- mice with CKD. by Noelia Torremadé (3687523)

Supplementary Material for: Use of the Myocardial Performance Index in Decreased Fetal Movement Assessment: A Case-Control Study by Ho D. (4108837)

“…<p><b><i>Objectives:</i></b> To determine whether there are any fetal cardiac function changes, as measured by the myocardial performance index (MPI), in pregnancies complicated by decreased fetal movement (DFM). <b><i>Methods:</i></b> We performed a prospective cross-sectional case-control study of 50 DFM and 50 uncomplicated third-trimester pregnancies matched within 2 gestational weeks. …”